With CVC out of the race, Bodycote's shareholders will vote on 21 October on Veritas Capital's board-backed 940p-per-share cash offer.
Bodycote (LSE:BOY) is approaching the decisive stage of its sale to US Private Equity firm Veritas Capital, with the FTSE 250 heat treatment and thermal processing specialist set to hold the Shareholder meetings needed to approve the deal later this month. In the meantime, the company's announcement feed has been crowded with Form 8.3 and Form 8.5 disclosures, along with a notification of a change in a major holding, as hedge funds, index trackers and market makers adjust their positions during the offer period.
The board-backed offer, announced on 1 September, is being made through Vulcan Alpha Bidco, a newly formed vehicle wholly owned by funds managed by Veritas. Shareholders are to receive a total value of 940p per share, comprising 932.8p in cash plus the 7.2p Interim Dividend already declared by Bodycote. The deal values the company's fully diluted share Capital at about £1.64 billion.
How the contest played out
The agreement marked the end of a busy year of bid interest. Earlier in 2026, Apollo made an approach worth around £1.5 billion but later walked away. In early August Bodycote then confirmed it had received possible cash offers from both CVC and Veritas, at 915p and 914p per share respectively including the interim dividend, and said its board would be minded to support either if a firm bid were made. The news lifted the shares by about 23% in a single session to around 923p.
Veritas ultimately raised its terms and secured the board's backing. CVC confirmed on 28 September that it would not make a firm offer, leaving the Veritas proposal as the only bid on the table. Bodycote's shares fell about 3% that morning to around 918p as hopes of a higher counterbid faded, although they remained well above their 52-week low of 585p.
What shareholders are being asked to approve
The scheme document was published on 28 September. The court meeting and general meeting are scheduled for 21 October in London. For the scheme to proceed, a majority in number of shareholders voting at the court meeting, representing at least 75% in value of the shares voted, must approve it, and a special resolution must pass at the general meeting. The scheme then requires court sanction and a number of regulatory clearances, and is expected to take effect in the first quarter of 2027. Once effective, Bodycote's shares will be Delisted from the London Stock Exchange.
The board has unanimously backed the deal and urged shareholders to vote in favour.
Trading momentum behind the bid interest
Private equity interest has been underpinned by a recovery in Bodycote's operating performance. In the first half of 2026, Revenue rose 3.3% to £381.2 million and adjusted operating profit increased 10.7% to £61.0 million, lifting the adjusted Operating Margin to 16.0%. Organic revenue in aerospace and defence grew by around 25%, while the Specialist Technologies division delivered organic growth of about 16.7%. The interim dividend was raised 4.3% to 7.2p.
That represented a turnaround from 2025, when revenue fell 4% and adjusted operating profit declined by just over 11%.
The Bodycote deal adds to a long list of FTSE 250 industrial companies being taken private this year. Unless the vote produces a surprise, the share price is likely to keep trading close to the offer value until completion.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...